The authors examine a proposal for new human embryo and embryoid guidelines, writing that before conducting any research beyond day 14, scientists must develop clear, thoughtful and culturally sensitive guidelines that include limitations and oversight procedures to ensure that science responds to societal needs and values.
Kirstin R.W. Matthews, Ana S. Iltis, Sam LoweDecember 21, 2021
This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.
Kirstin R.W. Matthews, Ana S. Iltis, Sarah HooverSeptember 22, 2021
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.
Kirstin R.W. Matthews, Ana S. Iltis, Daniel S. Wagner, Nuria Gallego Marquez, Jason Scott Robert, Inmaculada de Melo-Martín, Marieke Bigg, Sarah Franklin, Soren Holm, Ingrid Metzler, Matteo A. Molè, Jochen Taupitz, Giuseppe Testa, Jeremy SugarmanFebruary 26, 2021
The authors investigate the relationship between the number of freestanding emergency departments entering a local market and overall spending on emergency care. Academic Emergency Medicine: http://bit.ly/2pGwYMw
Freestanding emergency departments in Texas’ largest cities have not alleviated emergency room congestion or improved patient wait times in nearby hospitals, but they can reduce wait times in smaller communities, conclude the authors of this study.
The author determines that in 2016, freestanding emergency departments in Texas were more likely to be in areas that could yield high profits — i.e., areas with significantly higher household incomes — than in areas of high demand.
A growing number of stem cell clinics treat a variety of illnesses and injuries, yet few have conducted the necessary clinical research to ensure safety and efficacy.
The authors highlight the importance of collaboration between scientists, regulators, patients and patient advocates in developing effective policies and practices for unproven stem cell-based intervention clinics.
The authors explore the different scientific values and priorities that should be considered in setting the policy agenda for effectively combating neglected tropical diseases (NTDs) and argue that researchers and physicians should participate in this process.